VIDEO: ACCORD-2 highlights safety, efficacy data of AXS-05 for Alzheimer's disease agitation

In this video, George T. Grossberg, MD, discusses results from the ACCORD-2 study presented at the Alzheimer’s Association International Conference. The phase three study evaluated AXS-05 (dextromethorphan and bupropion; Axsome) for the treatment of agitation associated with Alzheimer’s disease. AXS-05 met the primary endpoint for efficacy and demonstrated a tolerable safety